|
|
|
|
Vol. 302, Issue 2, 814-821, August 2002
Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom
| |
Abstract |
|---|
|
|
|---|
The effects of chronic exposures (nine, 48 h apart) of conscious
guinea pigs to lipopolysaccharide (LPS) (30 µg · ml
1, 1 h) on airway function, airway histology (in
particular, goblet cell numbers), and inflammatory cell infiltration of
the lungs were examined as a model of chronic inflammatory lung
disease, such as chronic obstructive pulmonary disease. The
sensitivity of these parameters to treatment with the corticosteroid,
dexamethasone, or the phosphodiesterase-4 (PDE4) inhibitor, rolipram,
was determined. As the number of LPS exposures increased, there was a
progressively persistent bronchoconstriction after each exposure. After
nine LPS exposures, there was evidence on histological examination of
airway infiltration of, predominantly, neutrophils in perivascular, peribronchial, and alveolar tissues. After chronic LPS exposure, the
airway epithelium possessed a marked goblet cell hyperplasia and
evidence of inflammatory edema, features contributory to reduced airway
caliber. Treatment with dexamethasone (20 mg · kg
1) or rolipram (1 mg · kg
1),
administered (i.p.) 24 and 0.5 h before exposure and 24 and 47 h after each subsequent exposure, attenuated the inflammatory cell infiltration into the airway, goblet cell hyperplasia, and inflammatory edema. Dexamethasone exacerbated, whereas rolipram reversed, the chronic LPS-induced bronchoconstrictions. This study demonstrates that chronic LPS causes persistent bronchoconstriction, neutrophilic airway inflammation, goblet cell hyperplasia, and edema. These rolipram-sensitive features suggest the potential of PDE4
inhibitors in chronic inflammatory lung diseases.
| |
Introduction |
|---|
|
|
|---|
Chronic
mucus hypersecretion is an important symptomatic and pathological
feature of a heterogeneous group of chronic respiratory diseases that
includes chronic bronchitis, chronic obstructive pulmonary disease
(COPD), and asthma (Rogers, 1994
; Jackson, 2001
). Persistent mucus
overproduction contributes to reduced airway caliber and the occlusion
of small airways (reduced FEV1), productive cough, and labored breathing (Jackson, 2001
). Individuals with chronic
mucus hypersecretion also suffer from an increased frequency and
duration of respiratory infection, causing further exacerbation of
their original respiratory pathology (Jackson, 2001
).
The two major sources of mucus secretion in the respiratory tract are
the surface epithelial goblet cells and mucous cells of the submucosal
glands. In normal lungs, goblet cells are present in the large bronchi,
becoming increasingly sparse toward the bronchioles. The submucosal
glands are restricted to the large airways with their density
decreasing with airway caliber, such that they are absent in the
bronchioles. In chronic respiratory diseases, such as COPD and asthma,
submucosal glands increase in size (hypertrophy), and the number of
goblet cells is increased (hyperplasia), becoming more dense in the
peripheral airways, via a phenotypic conversion of nongoblet epithelial
cells (metaplasia) (Rogers, 1994
; Jackson, 2001
). The increased ratio
of goblet cells to ciliated cells and the increased goblet cell density
in terminal bronchioles, under conditions of hypersecretion, impairs
clearance of mucus through mucociliary mechanisms or coughing,
respectively. Lung histology from patients affected by COPD and asthma
also shows the presence of edema, which can further reduce airway
caliber and compromise lung function. A marked airway infiltration of macrophages and granulocytes is also present, principally neutrophils in COPD and eosinophils in asthma (Postma and Kerstjens, 1998
). In
clinical studies, these inflammatory parameters have been shown to
correlate with a reduction in lung function
(FEV1) and an exaggerated bronchoconstriction
[airway hyperreactivity (AHR)] to nonspecific stimuli (Postma and
Kerstjens, 1998
).
Anti-inflammatory steroids are the current mainstay of severe asthma
treatment (British Thoracic Society et al., 1993
), by inhibiting the
transcription of proinflammatory mediators [e.g., eicosanoids,
interleukins (IL), and tumor necrosis factor-
(TNF-
)], inducible
enzymes [e.g., nitric-oxide synthase, and
cyclooxygenase-2 (COX-2)], and adhesion molecules (Laitinen et al.,
1992
; Barnes and Adcock, 1993
). However, little evidence exists of
their clinical benefit on disease progression in COPD (Burge, 1999
).
Recently, attention has focused on the inhibition of phosphodiesterase
isoenzyme-4 (PDE4) as a molecular target for COPD (and asthma) (Torphy
et al., 1999
). Evidence suggests that the subsequent intracellular elevation in cAMP induces airway smooth muscle relaxation, alleviates inflammatory edema, and suppresses immunocompetent cell activation and
migration in models of acute pulmonary inflammation (Sekut et al.,
1995
; Torphy et al., 1999
).
The acute symptoms of mucus hypersecretion, as in chronic bronchitis,
can be modeled by exposure of rats to ozone or sodium metabisulfite
(Murlas and Roum, 1985
; Shore et al., 1995
). Features of severe asthma
(goblet cell hyperplasia, AHR, and eosinophilic airway infiltration)
have been mimicked by chronic antigen exposure of atopic mice and
guinea pigs (Blyth et al., 1998
; Danahay and Broadley, 1998
). However,
few in vivo models emulate the chronic inflammation of COPD, afford the
examination of lung function over many days (without anesthesia
influencing vagal tone or sensory reflexes), and stimulate the mucus
hypersecretion associated with neutrophilia and AHR. A single
exposure of rats to lipopolysaccharide (LPS) has been shown to cause an
acute lung neutrophilia and AHR, attenuated by TNF-
inhibition
(Kipps et al., 1992
). Previously, we have demonstrated in conscious
guinea pigs that chronic (nine, 60-min exposures, 48 h apart)
inhalation of aerosolized LPS causes further features analogous to
COPD, namely, a progressive decline in lung function, persistent AHR,
and a neutrophilic inflammatory cell population in the bronchoalveolar
fluid, together with nitric oxide overproduction (Toward and Broadley,
2001
). Mediators derived from inflammatory cell activation,
recruitment, and LPS are thought to induce epithelial proliferation,
permeability, and a mucus hypersecretory phenotype (Rogers, 1994
;
Jackson, 2001
). In this study, we therefore extend our previous
research to examine the morphological changes to the lung that underlie
the functional pathology associated with chronic LPS exposure.
The first aim of this study was to characterize the relationship between the previously described lung function and inflammatory cell influx and the lung morphology after single or chronic exposures to LPS. We regard the latter as more clinically relevant to chronic pulmonary inflammatory diseases, such as COPD. The second aim was to examine whether the corticosteroid, dexamethasone, or the PDE4 inhibitor, rolipram, affected the morphological changes as well as the functional parameters of acute and chronic LPS-induced inflammation.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. Groups of six male Dunkin-Hartley guinea pigs, weighing 300 to 400 g, were used. Animals received food and water ad libitum, and room temperature (22 ± 2°C) and lighting (maintained on a 12-h cycle) were regulated. This work complied with the Guidelines for Care and Use of Laboratory Animals, according to the Animals (Scientific Procedures) Act of 1986 and GlaxoSmithKline policy.
Measurement of Respiratory Function.
Airway function
[specific airway conductance (sGaw)] was monitored in conscious
guinea pigs, using whole body plethysmography as previously described
by Griffiths-Johnson et al. (1988)
. A computerized data acquisition
system replaced the original oscilloscope and angle resolver (Danahay
and Broadley, 1997
). Guinea pigs with a close-fitting face mask were
placed in a restrainer that was then slid into the plethysmography
chamber. A computer with a Biopac data acquisition system and
AcqKnowledge software (Biopac Systems Inc., Santa Barbara, CA) acquired
and stored data referring to the airflow across a pneumotachograph
(Mercury FIL; GM Instruments, Ltd., Scotland, UK) as the animal
breathed. The resulting change in box volume (pressure) was also
simultaneously measured. Changes in airflow and box pressure were
measured by two UP pressure transducers (Pioden Controls Ltd.,
Canterbury, UK). The resultant waveforms could then be rapidly analyzed
by comparing the gradients of the flow and the box pressure waves at a
point where flow tended toward zero, i.e., in the first 30 ms of
expiration. A function of these parameters, correcting for ambient
pressure and the weight of the animal, determined a value for sGaw. At
least five breaths were analyzed for each animal at each time point.
Before all experiments, the animals were handled and familiarized with
the apparatus to reduce stress.
Inhalation Exposures and Administration of Anti-Inflammatory
Compounds.
Groups (n = 6) of guinea pigs were
exposed to LPS or the LPS vehicle (saline) with or without treatment
with dexamethasone or rolipram as shown in Fig.
1 and as previously described (Toward and
Broadley, 2001
). In single exposure studies, guinea pigs were exposed
in an exposure chamber (620 × 300 × 420 mm) for 1 h to an aerosolized solution of LPS (30 µg · ml
1, endotoxin from Escherichia coli
serotype O26:B6) (Sigma Chemical Co., Poole, Dorset, UK) or saline
(NaCl for infusion British Pharmacopoea, 0.9% w/v) (Baxter
Healthcare, Thetford, Norfolk, UK). The aerosol was generated by a
Wright nebulizer driven by compressed air at 20 p.s.i., at a rate
of 0.5 ml · min
1. In chronic exposure
studies, the animals received nine exposures, 48 h apart. The
lethal dose of LPS (LD50 within 24 h, 0.7 mg · kg
1, i.p.) in guinea pigs was
considered substantially higher than that administered in this study
(Matsuda et al., 1995
). The average of two sGaw measurements was
obtained prior to exposure (baseline or 47 h after the previous
exposure) and then at regular intervals (0, 15, 30 min, and hourly)
after exposure(s).
|
1) or rolipram
(1 mg · kg
1) were administered (i.p.) 24 and 0.5 h before the first of the chronic exposures to LPS or
saline and at 24 and 47 h after each subsequent exposure. Animals
treated with rolipram during the chronic LPS study developed persistent
bronchodilation, which would have interfered with an assessment of
airway reactivity to histamine 24 h after the ninth exposure.
Consequently, the last dose of rolipram was given 24 h after the
eighth exposure to LPS or saline, which allowed sGaw to recover to
baseline values, at 24 h after the ninth LPS exposure. Dexamethasone-21-phosphate, disodium salt (Sigma Chemical), and rolipram (Sigma Chemical) stock solutions were dissolved in 50% dimethyl sulfoxide (Sigma Chemical), 50% saline (Baxter Healthcare) and further diluted with saline for injection (1.0 ml). The final concentration of dimethyl sulfoxide was less than 5%, and this vehicle
has previously been shown by this laboratory to have no effect on
airway responses or inflammation in a similar chronic inflammatory
model (Danahay and Broadley, 1998
1,
i.p.; Euthatal; Rhone Merieux, Essex, UK), and the trachea was cannulated. A 1% solution of EDTA disodium salt (Sigma Chemical) was
flushed through the cannula into the lungs (1 ml · 100 g
1 of body weight), recovered 3 min later, and
repeated once.
Lung Histology.
After lavage, the lungs were fixed by slow
in situ inflation with neutral-buffered formalin (10%, pH 7.0) (1 ml · 100 g
1 of body weight) via the
tracheal cannula and, following immediate removal from the thoracic
cavity, further immersed in neutral-buffered formalin for at least
72 h. After fixation, representative samples were cut through the
large bronchi of the right and left lung (medial lobe), dehydrated in
70 to 100% ethanol/xylene, and embedded in paraffin wax. Sections were
cut (6 µm), deparaffinized, and stained with hematoxylin and eosin or
Masson's trichrome for general morphology. Additional sections were
stained with elastic van Gieson stain to differentiate elastic fibers
and collagen, and Alcian Blue-periodic acid Schiff (ABPAS) was used for
identification of mucin (neutral and acid)-containing cells.
Data Analysis.
To reduce intersubject variability, changes
in sGaw from the baseline sGaw values taken before a procedure are
presented as a percentage of the mean baseline value preceding
the first LPS or saline challenge. Absolute values of baseline sGaw are
stated in the figure legends. Significance of differences in the number of airway epithelial goblet cell was compared using analysis of variance, followed by Scheffe's post hoc analysis. Changes in airway
function were compared using analysis of variance followed by the
appropriate paired or unpaired Student's (two-tailed) t test. Differences were considered statistically significant at p < 0.05 (Motulsky, 1995
).
| |
Results |
|---|
|
|
|---|
Airway Function
Effects of Chronic Exposure to LPS on Airway Function.
The
first exposure to LPS in the chronic exposure study caused an immediate
bronchoconstriction (
12.4 ± 10.7% decrease from baseline sGaw
values), which recovered 15 to 30 min later but was not significantly
different (p > 0.05) from the response to saline
(
20.5 ± 3.6%) (Fig. 2). The
seventh, eighth, and ninth exposures to LPS caused a decline in sGaw
(
16.9 ± 5.9,
20.6 ± 2.8, and
23.1 ± 3.6 peak
percentage decrease from baseline sGaw values), with a progressive
increase in duration of bronchoconstriction. After the eighth exposure,
there was still significant bronchoconstriction at 30 min (Fig. 2D),
whereas after the ninth exposure, the bronchoconstriction remained
until 19 h after exposure (Fig. 2B).
|
Effects of Dexamethasone or Rolipram Treatment on the Airway Function Responses to Chronic LPS Exposures. Dexamethasone or rolipram treatment did not significantly affect (p > 0.05) the initial LPS-induced bronchoconstriction after the first exposure. However, dexamethasone exaggerated the duration of prolonged bronchoconstriction after the ninth LPS exposure, from 19 h to at least 24 h after exposure (Fig. 2C). In contrast, rolipram-treated animals developed a significant (p < 0.001) and persistent bronchodilation at 24 and 47 h after the seventh exposure to LPS (Fig. 2D). When rolipram was withdrawn 24 h after the eighth exposure to LPS, bronchodilation returned to baseline sGaw values at 24 h after the ninth exposure. No bronchodilator activity occurred in rolipram-treated animals exposed to chronic saline (data not shown). Lung function did not differ in the absence or presence of dexamethasone or rolipram treatment in saline-exposed animals (data not shown).
Lung Morphology
Effects of Single or Chronic Exposures to LPS on the Upper
Airways.
Large bronchial sections, stained with ABPAS, from the
lungs of naive animals or those removed 24 h after a single or
chronic saline exposure (Fig. 3A),
appeared to possess a normal composition of epithelial cells with an
occasional darkly stained goblet cell. Compared with naive animals, at
24 h after a single LPS exposure, the number of goblet cells
increased 107% (p > 0.05) (Fig.
4). However, at 24 h after chronic
LPS exposure, the ratio of goblet cells containing both acid (purple)
and neutral (magenta) mucins to normal columnar-ciliated cells was
greatly increased (Fig. 3B). Chronic LPS exposure caused significant
(p < 0.05) 4.6- and 2.5-fold increases, respectively,
in the number of goblet cells (hyperplasia) compared with naive and
chronic saline-exposed animals (Fig. 4). In chronically LPS-exposed
animals, there was also an increased number of Clara cells,
anatomically defined by their nonciliated, dome-shaped appearance and
protrusion into the bronchiolar lumen, although they were not
quantified. In all the sections analyzed, no obvious evidence of airway
smooth muscle hypertrophy, collagen disposition beneath the basement
membrane, or change in elastic fiber composition was present.
|
|
Effect of Dexamethasone or Rolipram Treatment on Airway Goblet Cells after Single or Chronic Exposure to LPS. Treatment with dexamethasone or rolipram greatly attenuated the chronic LPS-induced goblet cell hyperplasia (Fig. 3, C and D, respectively). The increased population of goblet cells 24 h after chronic LPS exposure was significantly (p < 0.05) inhibited by 89 and 71% in animals treated with dexamethasone or rolipram, respectively (Fig. 4). Neither dexamethasone nor rolipram treatment caused a significant change in the airway goblet cell population 24 h after chronic saline (Fig. 4).
Effects of Single or Chronic Exposures to LPS on Lung Alveoli.
Peripheral lung sections, stained with Masson's trichrome, from the
lungs of naive animals or those removed 24 h after a single or
chronic saline exposure (Fig. 5A) had
normal alveolar pathology and no evidence to indicate an increased
number of resident macrophages or granulocytes in the alveoli. However,
at 24 h after a single LPS exposure, there was an increased
migration of macrophages and neutrophils into the perivascular,
peribronchial tissues and alveoli, which was further increased at
24 h after chronic LPS exposure (Fig. 5B). In chronic LPS-exposed
animals, there was also some evidence of an increase in the alveolar
wall thickness and edema. Edematous protein-rich fluid (defined by
heavy eosin staining) was also present, presumably exuded from the
vasculature into the alveolar lumen.
|
Effect of Dexamethasone or Rolipram Treatment on Alveoli after
Chronic Exposure to LPS.
Treatment with dexamethasone or rolipram
reduced the chronic LPS-induced infiltration of leukocytes from
perivascular sites into the airways and alveoli. Treating the animals
with rolipram greatly attenuated the amount of proteinaceous fluid in
the alveolar spaces (Fig. 6C), whereas
dexamethasone also appeared to reduce the chronic LPS-induced edema,
but to a lesser extent (Fig. 6D).
|
| |
Discussion |
|---|
|
|
|---|
Chronic airflow obstruction and AHR are characteristic features of
patients with COPD and severe asthma (Laitinen et al., 1992
; Postma and
Kerstjens, 1998
). In COPD, there are increased numbers of inflammatory
cells (predominantly neutrophils) in the airway wall, particularly in
the epithelial layer and around the bronchial submucosal glands (Postma
and Kerstjens, 1998
). Persistent airway inflammation in these patients
results in airway wall edema, deposition, and remodeling of connective
tissue components (e.g., submucosal and adventitial collagen
disposition), together with hypertrophy and hyperplasia of submucosal
glands or the goblet cell phenotype, respectively (Barnes, 1998
;
Jackson, 2001
). These pathological features reduce airway caliber and
are thought to contribute to the heightened constrictor response from
spasmogenic stimuli (AHR) and airflow obstruction in COPD (Pare and
Hogg, 1989
). In this study, we examined the functional and
morphological effects of chronic pulmonary inflammation derived from
repeated exposure of guinea pigs to LPS as a model for the progressive inflammatory processes of COPD and the ability of dexamethasone and
rolipram to suppress these changes.
The first exposure to LPS caused a small bronchoconstriction that was
no different from that observed after saline inhalation (Toward and
Broadley, 2000
), which we have previously attributed to the saline
condensing in the airways or to obstructed airway conductance (Toward
and Broadley, 2001
). By the ninth exposure to LPS, there was a
prolonged period of bronchoconstriction, which did not occur with
repeated saline exposure. Previously, we have reported that the influx
of inflammatory cells into the lungs as measured by BAL, particularly
neutrophils, increases with the number of exposures. Also, AHR to
histamine was prolonged from 2 h after a single exposure to at
least 24 h after the eighth exposure (Toward and Broadley, 2001
).
In the present study, we further demonstrate infiltration of
neutrophils and macrophages into the alveolar, perivascular, and
peribronchial spaces after chronic LPS exposure.
The increased infiltration of neutrophils into the BAL fluid and lung
tissues was likely to be initially orchestrated by chemotactic factors,
such as TNF-
and IL-8, released into the airways by resident
macrophages, epithelial cells, and lymphocytes (Snella and Rylander,
1985
; Brigham and Meyrick, 1986
; Kipps et al., 1992
). The early
synthesis of TNF-
(Brigham and Meyrick, 1986
) in response to LPS,
activates other proinflammatory mediators, including arachidonic acid
metabolites, deleterious cytotoxins (proteases and reactive oxygen
species), and cytokines. Bronchial biopsies from patients with COPD
show similar inflammatory processes, and sputum samples have elevated
TNF-
, IL-8, reactive oxygen species, and proteolytic enzyme levels
(Barnes, 1998
). The eicosanoid products of arachidonic acid, namely
leukotrienes (B4, C4,
D4, and E4),
platelet-activating factor (PAF), and inducible COX-2-derived
prostanoids [thromboxane, prostaglandin (PG)-F2,
-D2, and 8-epi-PGF2] have
all been implicated in animal models, COPD, and asthma as causes of
AHR, bronchoconstriction, increased airway permeability or leukocyte
influx (Brigham and Meyrick, 1986
; Laitinen et al., 1992
; Barnes, 1998
;
Barnes et al., 1999
).
In this study, histological examination of the lungs after a single LPS
exposure showed no morphological features to support a geometric
reduction in airway caliber that would potentiate a spasmogen-induced
airway narrowing and explain the AHR seen previously with this model
(Pare and Hogg, 1989
). However, in chronically LPS-exposed animals, the
airway histology showed extensive migration of neutrophils but little
evidence of airway collagen or elastic fiber remodeling, smooth muscle
hypertrophy, or epithelial shedding. Both dexamethasone and rolipram
were equieffective at attenuating the chronic LPS-induced airway
infiltration of inflammatory cells, possibly due to their inhibitory
effect on TNF-
production (Barnes et al., 1999
; Torphy et al.,
1999
).
Histological examination after chronic LPS exposure also revealed
increased alveolar wall thickness and evidence of edema and plasma
exudation. The inflammatory edema observed after chronic LPS exposure
may be a result of an increased capillary blood pressure by
vasoconstrictor eicosanoids or an increased permeability of the
capillary wall from the release of reactive oxygen species (including
NO and peroxynitrite), eicosanoids, or proteolytic enzymes (Brigham and
Meyrick, 1986
; Barnes et al., 1999
). Edematous swelling of the airway
wall and increased airway exudate in the lung have been shown to reduce
airway caliber and correlate with AHR in sheep (Hwang et al., 2001
),
and may contribute to the AHR observed in the present chronic LPS
model. Edema is also a probable contributor to the prolonged
bronchoconstriction seen in this study after chronic LPS exposure. The
edema and accumulation of proteinaceous fluid in the alveoli was
inhibited by rolipram to a greater extent than by dexamethasone. This
may indicate an increased potency of rolipram on granulocyte
infiltration into the airway and a subsequent release of edema-inducing
mediators. It may also explain why the prolonged bronchoconstriction
following the final LPS challenge was attenuated by rolipram but not by
dexamethasone and adds weight to the conclusion that the prolonged
bronchoconstriction was associated with the edema. The generation of
inducible COX-2-derived prostanoids, PAF, and leukotrienes may also
contribute to the prolonged chronic LPS-induced bronchoconstrictions.
In airway epithelial and smooth muscle cell cultures, dexamethasone
inhibits COX-2 expression and the subsequent release of
bronchoconstrictor prostanoids (Barnes et al., 1999
). However, in this
study, dexamethasone exacerbated the later LPS-induced
bronchoconstrictions. This may be due to inhibition of expression of
the functionally antagonistic COX-2-derived bronchodilator,
PGE2 (Barnes et al., 1999
). The persistent
bronchodilation in rolipram-treated animals during later LPS
challenges, but not saline exposures, may be due to an induction of the
COX-2-derived PGE2 by rolipram. The
bronchodilatory second messenger of PGE2 is cAMP,
the levels of which will be elevated by PDE4 inhibition with rolipram
(Uhlig et al., 1995
; Barnes et al., 1999
).
AHR after chronic LPS exposures may have been due to the formation of
the powerful oxidant peroxynitrite from the interaction of
inflammatory-derived superoxide with NO (Beckman, 1996
; Barnes et al.,
1999
), excessive airway levels of which occur in chronic LPS-exposed
animals (Toward and Broadley, 2001
). Peroxynitrite can induce AHR in
guinea pigs (Sadeghi-Hashijin et al., 1996
), possibly through cytotoxic
damage of the airway epithelium to expose sensory nerves (Barnes et
al., 1999
) or an impairment of
-adrenoceptors (Kanazawa et al.,
1999
). Levels of peroxynitrite or the peroxynitrite-induced nitration
product, nitrotyrosine, were not, however, determined in the current study.
The major histological change observed after chronic LPS exposures was
an increase in the density of goblet cells in the epithelial layer. The
close proximity of inflammatory cells to the epithelial goblet cells
and submucosal glands in the histology of patients with COPD suggests a
causative association between leukocytes and the hypersecretory mucus
phenotype (Postma and Kerstjens, 1998
). Human airways possess a large
number of submucosal glands and goblet cells, whereas in guinea pig
airways, goblet cells are the predominant source of mucus secretion
(Jackson, 2001
). In guinea pigs, neuronal (cholinergic, adrenergic, and
peptidergic) control of mucus secretion appears to be via the goblet
cells, whereas in humans, it is the submucosal glands that are
predominantly innervated. However, in both guinea pigs and humans,
inflammatory mediators act on goblet cells directly (and also via
neuronal mechanisms in guinea pigs) to influence mucus secretion.
Consequently, despite these species differences in the mechanistic
regulation and source of mucus secretion, this model of LPS-induced
goblet cell hyperplasia has clinical relevance, as the majority of
airflow obstruction in COPD and asthma occurs in the smaller airways, where goblet cells but not submucosal glands are expressed. In this
study, a single exposure to LPS caused only a slight increase in goblet
cells 24 h later. However, after chronic LPS exposure, the
epithelial goblet cells were greatly increased. The peribronchial migration of activated leukocytes into the airway lumen and persistent exposure to proinflammatory stimuli are likely to contribute to goblet
cell up-regulation, although the degree of hyperplastic and metaplastic
mechanisms involved in the derivation of this phenotype are unclear
(Rogers, 1994
). Contrary to the T-helper 2 (TH2)-derived inflammation in asthmatics, LPS
causes a predominantly TH1-favored cytokine
response (Blyth et al., 1998
; Barnes et al., 1999
). This imbalance in
TH expression appears to affect the mechanism of
goblet cell induction. Shimizu et al. (2000)
showed in atopic rats
exposed to antigen that leukotrienes (C4,
D4, and E4) are potent
secretagogues and inhibitors of ciliary beat frequency, and play an
important role in goblet cell hyperplasia, whereas in LPS-inoculated
animals, neutrophil- and COX-derived products were important (Barnes et
al., 1999
). Neutrophil-derived reactive oxygen species have been shown
to enhance mucin release in guinea pig tracheal and human bronchial
epithelial cells via a NO-dependent pathway, an effect blocked by
COX inhibition (Wright et al., 1996
; Barnes et al., 1999
). In the
current study, neutrophil-derived superoxide, the excess airway NO
after chronic LPS inhalation (shown in our previous study, Toward and
Broadley, 2001
) and their combined product, peroxynitrite, could
stimulate mucus secretion and goblet cell hyperplasia (Beckman, 1996
;
Wright et al., 1996
; Barnes et al., 1999
). Inflammation-derived
prostanoids, PAF, and proteolytic enzymes are also capable of
stimulating goblet cell mucus secretion and hyperplasia, exacerbating
the reduction in airway caliber after chronic LPS exposure (Barnes et
al., 1999
). Both dexamethasone and rolipram attenuated goblet cell
hyperplasia after chronic LPS exposure. Suppression of inflammatory
cell activity with rolipram or dexamethasone reduces the production of
reactive oxygen species, eicosanoids, and protease, which stimulate
goblet cell secretion and contribute to the etiology that induces a
hypersecretory phenotype and edema after chronic LPS (Barnes and
Adcock, 1993
; Torphy et al., 1999
).
In conclusion, this study demonstrates that morphological changes to the airways, including neutrophil infiltration, edema, and goblet cell hyperplasia, following chronic LPS exposure of conscious guinea pigs are associated with functional changes of persistent bronchoconstriction. These changes, along with the persistent AHR observed in our previous study, are characteristic features of COPD. Both dexamethasone and rolipram attenuated goblet cell hyperplasia and edema, probable contributors of the reduced airway caliber and AHR, via attenuation of LPS and inflammatory cell-derived proinflammatory mediators. In common with COPD, in which steroids have only modest beneficial effects, primarily on quality of life, in this study, dexamethasone failed to improve a deficit in lung function. Rolipram, however, improved lung function. The conscious guinea pig chronically exposed to LPS may therefore prove a useful model of COPD, and the results support the further development of PDE4 inhibitors for the treatment of COPD or severe asthma.
| |
Acknowledgments |
|---|
We gratefully acknowledge Dr. A. T. Nials of the Respiratory Diseases Unit, GlaxoSmithKline Research and Development, Stevenage, UK, for assistance in conducting this work and critical reading of the manuscript. We also thank Derek Scarborough of the Histology Department, Biosciences Department, Cardiff University, Cardiff, UK, for the invaluable contributions of processing, cutting, and staining of lung tissue, and Michael Pedrick and Tony Savage of the Histopathology Group, GlaxoSmithKline Research, Stevenage, UK, for histological interpretation.
| |
Footnotes |
|---|
Accepted for publication April 8, 2002.
Received for publication February 6, 2002.
This work was financially supported through a GlaxoSmithKline studentship (to T.J.T.).
DOI: 10.1124/jpet.102.033951
Address correspondence to: Professor Kenneth J Broadley, Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff CF10 3XF, UK. E-mail: broadleykj{at}cardiff.ac.uk
| |
Abbreviations |
|---|
COPD, chronic obstructive pulmonary disease;
AHR, airway hyperreactivity;
IL, interleukin;
TNF-
, tumor necrosis
factor-
;
COX, cyclooxygenase;
PDE4, phosphodiesterase isoenzyme-4;
LPS, lipopolysaccharide;
sGaw, specific airway conductance;
BAL, bronchoalveolar lavage;
ABPAS, Alcian Blue-periodic acid Schiff;
PAF, platelet-activating factor;
PG, prostaglandin;
FEV1, forced
expiratory volume in 1 s;
TH, T-helper cells;
GC, goblet cell.
| |
References |
|---|
|
|
|---|
2-adrenoceptor agonists by peroxynitrite in guinea-pig airways.
Am J Respir Crit Care Med
159:
1272-1276This article has been cited by other articles:
![]() |
J. L. Wright, M. Cosio, and A. Churg Animal models of chronic obstructive pulmonary disease Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L1 - L15. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 468 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Mucenski, J. M. Nation, A. R. Thitoff, V. Besnard, Y. Xu, S. E. Wert, N. Harada, M. M. Taketo, M. T. Stahlman, and J. A. Whitsett {beta}-Catenin regulates differentiation of respiratory epithelial cells in vivo Am J Physiol Lung Cell Mol Physiol, December 1, 2005; 289(6): L971 - L979. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-F. Tang, Y.-H. Song, J.-C. Chen, J.-Q. Chen, and P. Wang Upregulation of Phosphodiesterase-4 in the Lung of Allergic Rats Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 823 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Savkovic, J. Villanueva, J. R. Turner, K. A. Matkowskyj, and G. Hecht Mouse Model of Enteropathogenic Escherichia coli Infection Infect. Immun., February 1, 2005; 73(2): 1161 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Mata, B Sarria, A Buenestado, J Cortijo, M Cerda, and E J Morcillo Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells Thorax, February 1, 2005; 60(2): 144 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Toward, N. Smith, and K. J. Broadley Effect of Phosphodiesterase-5 Inhibitor, Sildenafil (Viagra), in Animal Models of Airways Disease Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 227 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.R.M. Rocco, D.P. Momesso, R.C. Figueira, H.C. Ferreira, R.A. Cadete, A. Legora-Machado, V.L.G. Koatz, L.M. Lima, E.J. Barreiro, and W.A. Zin Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury Eur. Respir. J., July 1, 2003; 22(1): 20 - 27. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||